1200188

: FORM D



UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4 (6), AND/OR

UNIFORM LIMITED OFFERING EXEMPTION

OWB	Approval
OMB Number:	3235-0076
Expires:	May 31, 2005
Estimated aver	age burden
hours per resp	onse 1.0

hours per response ...

SEC USE	ONLY
Prefix	Serial
DATE RE	CEIVED

Name of Offering (check if this is an amendment and name has changed, and indicate change.) Series B Convertible Preferred Offering	
Filing Under (Check box(es) that apply): Rule 504 Rule 505 Rule 506 Section 4	4(6) ULOE PROCESSE
Type of Filing: New Filing Amendment	
A. BASIC IDENTIFICATION DATA	/ 3014 0 2
1. Enter the information requested about the issuer	THOMSON
Name of Issuer check if this is an amendment and name has changed, and indicate change.)	FINANCIAL
Vantage Oncology, Inc.	
Address of Executive Offices (Number and Street, City, State, Zip Code) 880 Apollo Street, Suite 329, El Segundo, CA 90245	Telephone Number (Including Area Code) (310) 335-4000
Address of Principal Business Operations (Number and Street, City, State, Zip Code) (if different from Executive Offices)	Telephone Number (Including Area Code)
Brief Description of Business Operating oncology radiation therapy facilities.	SECMAIL
Type of Business Organization I corporation I limited partnership, already formed business trust I limited partnership, to be formed	ther (please specify)?
Actual or Estimated Date of Incorporation or Organization: Month Year Actual or Estimated Date of Incorporation or Organization: Genter two-letter U.S. Postal Service abbreviation for CN for Canada; FN for other foreign jurisdiction)	Actual Estimated

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1972 (2-99) 1 of 8



A. BASIC IDENTIFICATION DATA		
2. Enter the information requested for the following:		
• Each promoter of the issuer, if the issuer has been organized within the past five year		
 Each beneficial owner having the power to vote or dispose, or direct the vote or dispose securities of the issuer; 	sition of, 10% or me	ore of a class of equity
• Each executive officer and director of corporate issuers and of corporate general and r	managing partners of	f partnership issuers; and
• Each general and managing partner of partnership issuers. _{N/A}		
Check Box(es) that Apply: Promoter Beneficial Owner Executive Offi	icer 🗵 Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		
Fiore, Michael Thomas		
Business or Residence Address (Number and Street, City, State, Zip Code) 880 Apollo Street, Suite 329, El Segundo, CA 90245		
Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Offi	icer 🗵 Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		
Felsenthal, Martin		
Business or Residence Address (Number and Street, City, State, Zip Code)		
30 Burton Hills Blvd., Suite 370, Nashville, TN 37215		
Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Offi	icer 🗵 Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	· ·	
Lubash, Barbara N.		
Business or Residence Address (Number and Street, City, State, Zip Code)		
450 Newport Center Drive, Suite 380, Newport Beach, California 92260		
Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☑ Executive Offi	icer Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		
Salomon, Marshal D.		
Business or Residence Address (Number and Street, City, State, Zip Code)		
880 Apollo Street, Suite 329, El Segundo, CA 90245		
Check Box(es) that Apply: Promoter Beneficial Owner Executive Off	icer 🗵 Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual) Aspinwall, Michael E.		
Business or Residence Address (Number and Street, City, State, Zip Code)		
City Place II, 185 Asylum Street, Hartford, Connecticut 06103		
Check Box(es) that Apply: ☐ Promoter ☑ Beneficial Owner ☑ Executive Off	icer X Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual) Botnick, Leslie, M.D.	_	
Business or Residence Address (Number and Street, City, State, Zip Code)		
20945 Devonshire Street, Suite 103, Chatsworth, California 91311		
Check Box(es) that Apply: ☐ Promoter ☑ Beneficial Owner ☐ Executive Off	icer 🗆 Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		
Conning Capital Partners VI, L.P.	·	
Business or Residence Address (Number and Street, City, State, Zip Code)	1	
City Place II, 185 Asylum Street, Hartford Connecticut 06103		

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

A. BASIC IDENTIFICATION DATA		
2. Enter the information requested for the following:		
• Each promoter of the issuer, if the issuer has been organized within the past five years;		
 Each beneficial owner having the power to vote or dispose, or direct the vote or disposition securities of the issuer; 	n of, 10% or mo	ore of a class of equity
• Each executive officer and director of corporate issuers and of corporate general and management	aging partners of	f partnership issuers; and
Each general and managing partner of partnership issuers.		
Check Box(es) that Apply: ☐ Promoter ☑ Beneficial Owner ☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		
Versant Ventures Capital II, L.P.		
Business or Residence Address (Number and Street, City, State, Zip Code)		
450 Newport Center Drive, Suite 380, Newport Beach, California 92260		
Check Box(es) that Apply: ☐ Promoter ☑ Beneficial Owner ☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		
Salix Ventures II, L.P.		
Business or Residence Address (Number and Street, City, State, Zip Code)		
30 Burton Hills Blvd., Suite 370, Nashville, TN 37215		
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer	▼ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual) Grotting, John		
Business or Residence Address (Number and Street, City, State, Zip Code)		
10232 S. 51st Street, Phoenix, AZ 85044		
Check Box(es) that Apply: ☐ Promoter ☑ Beneficial Owner ☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual) New Enterprise Associates II, L.P.		
Business or Residence Address (Number and Street, City, State, Zip Code)		
2490 Sand Hill Road, Menlo Park, CA 94025		
Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		Tridinging Faither
Provinces on Providence Address Observation and Court City State 7in Code		:
Business or Residence Address (Number and Street, City, State, Zip Code)		
Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		
Business or Residence Address (Number and Street, City, State, Zip Code)		
Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	-	
Business or Residence Address (Number and Street, City, State, Zip Code)	-	

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

B. INFORMATION ABOUT OFFERING	
Answer also in Appendix, Column 2. if filing under ULOE.	(e) (N)
2. What is the minimum investment that will be accepted from any individual?	N/A
	(e) No ⊠ □
4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering.	
If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a	
state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only. None	
Full Name (Last name first, if individual)	
Business or Residence Address (Number and Street, City, State, Zip Code)	
Name of Associated Broker or Dealer	
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers	
(Check "All States" or check individual States)	All States
□ AL □ AK □ AZ □ AR □ CA □ CO □ CT □ DE □ DC □ FL □ GA □ HI □ IL □ IN □ IA □ KS □ KY □ LA □ ME □ MD □ MA □ MI □ MN □ MS	□ID □M0
MI DNE DNV DNH DNJ DNM DNY DNC DND DOH DOK DOR	□PA
RI SC SD TN TX OUT VT VA WA WV WI WY	□PR
Full Name (Last name first, if individual)	
Business or Residence Address (Number and Street, City, State, Zip Code)	
Name of Associated Broker or Dealer	
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers	
	All States
□AL □AK □AZ □AR □CÁ □CO □CT □DE □DC □FL □GA □HI	□ ID
IL IN IIA KS KY ILA ME MD MA MI MN MS	□M0
MT NE NV NH NJ NM NY NC ND 0H NOK NOR RI SC SD NT NTX NT NT NA NA NA NW NY NY	□PA □PR
Full Name (Last name first, if individual)	
Business or Residence Address (Number and Street, City, State, Zip Code)	
Name of Associated Broker or Dealer	
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers	
(Check "All States" or check individual States)	All States
IL IN IA OKS OKY OLA OME OMD OMA OMI OMS OMS	\square MO
MT DNE DNV DNH DNJ DNM DNV DNC DND DOH DOK DOR	□PA □PP
RI SC SD TN TX DUT VT VA WA WV WI WY (Use blank sheet, or copy and use additional copies of this sheet, as necessary.)	☐P R

3 of 8

i.	sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \(\sigma\) and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.				
	Type of Security	(Aggregate Offering Price	A	lmount Already Sold
	Debt	\$_		\$_	
	Equity	\$_			
	☐ Common ☐ Preferred				
	Convertible Securities (including warrants)	\$_	15,000,000.00	\$_	15,000,000.00
	Partnership Interests	\$_	0.00	\$	0.00
	Other ()	\$_	0.00	\$_	0.00
	Total	\$_	15,000,000.00	\$_	15,000,000.00
	Answer also in Appendix, Column 3, if filing under ULOE.				
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."				Aggragata
			Number Investors	Γ	Aggregate Pollar Amount of Purchases
	Accredited Investors		8	\$	15,000,000.00
	Non-accredited Investors	_	0	\$	0.00
	Total (for filings under Rule 504 only)			\$	0.00
	Answer also in Appendix, Column 4, if filing under ULOE.				
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.				
	Type of offering		Type of Security	D	Oollar Amount Sold
	Rule 505			\$_	0.00
	Regulation A			\$	0.00
	Rule 504		-	\$_	0.00
	Total			\$	0.00
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.				
	Transfer Agent's Fees			\$_	0.00
	Printing and Engraving Costs		🗆	\$ _	0.00
	Legal Fees		X	\$	120,000.00
	Accounting Fees		🗆	\$_	0.00
	Engineering Fees		🗆	\$_	0.00
	Sales Commissions (specify finders' fees separately)		🗆	\$ _	0.00
	Other Expenses (identify)		\square	\$_	0.00
	Total		<u>X</u>	\$	120,000,00

Salaries and fees	-0- 0,000.00 0,000.00 0,000.00 0,000.00
Purchase, rental or leasing and installation of machinery and equipment	0,000.00 0,000.00 0,000.00 0,000.00 0,000.00
Construction or leasing of plant buildings and facilities Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) Repayment of indebtedness Sas1,500 Working capital Other (specify): Travel and entertainment, miscellaneous Corporate G&A Column Totals Column Totals Total Payments Listed (column totals added) D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date Signature Date Signature Date Signature Date Title of Signer (Print or Type) Title of Signer (Print or Type)	0,000.00
Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) Repayment of indebtedness S \$\$1,500	0,000.00
offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) Repayment of indebtedness Working capital Other (specify): Travel and entertainment, miscellaneous Corporate G&A Corporate G&A Column Totals Column Totals Total Payments Listed (column totals added) D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Vantage Oncology, Inc. Name of Signer (Print or Type) Title of Signer (Print or Type) Title of Signer (Print or Type)	0,000.00
Working capital Other (specify): Travel and entertainment, miscellaneous \$\infty\$\$\frac{1}{2}\$\	0,000.00 0,000.00
Other (specify): Travel and entertainment, miscellaneous S 1,980 Corporate G&A	30,000.00
Column Totals Column Totals D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Vantage Oncology, Inc. Title of Signer (Print or Type) Title of Signer (Print or Type)	30,000.00
Column Totals Total Payments Listed (column totals added) D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Vantage Oncology, Inc. Name of Signer (Print or Type) Title of Signer (Print or Type)	80,000.00
Total Payments Listed (column totals added) D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Vantage Oncology, Inc. Title of Signer (Print or Type) Title of Signer (Print or Type)	80,000.00
Total Payments Listed (column totals added) D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Vantage Oncology, Inc. Title of Signer (Print or Type) Title of Signer (Print or Type)	 _
The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Vantage Oncology, Inc. Title of Signer (Print or Type)	00
Vantage Oncology, Inc. Name of Signer (Print or Type) Title of Signer (Print or Type)	
Name of Signer (Print or Type) Title of Signer (Print or Type)	
Name of Signer (Print or Type) Title of Signer (Print or Type)	ſ
· · ·	
Marshal D. Salomon Chief Financial Officer	

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

\$ 14,880,000.00

b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer."

	E. STATE SIGNATU	RE
Is any party described in 17 CFR 2 such rule? NOT APPLICABLE TO RULE 506 OFF See A	230.262 presently subject to any of the ERINGS Appendix, Column 5, for state response.	
The undersigned issuer hereby undert Form D (17 CFR 239.500) at such tin	•	of any state in which this notice is filed, a notice on
incore to offeren	akes to furnish to the state administrator ICABLE TO RULE 506 OFFERINGS	s, upon written request, information furnished by the
Limited Offering Exemption (ULO availability of this exemption has the		is that must be satisfied to be entitled to the Uniform filed and understands that the issuer claiming the issuer satisfied.
The issuer has read this notification and bundersigned duly authorized person.	knows the contents to be true and has duly	caused this notice to be signed on its behalf by the
Issuer (Print or Type) Vantage Oncology, Inc.	Signature	Date = 126/04
Name of Signer (Print or Type)	Title of Signer (Print or Type) Chief Financial Officer	-

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

					APPENDIX				
1	Intend to r accre inves St	to sell non- dited tors in ate -Item 1)	Type of Security and aggregate offering price offered in state (Part C-Item 1)		amount pur	investor and chased in State C-Item 2)	,	5 Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)	
State	Yes	No	Series B Convertible Preferred Stock	Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
AL			\$	\$			5		
AK			\$	\$			<u> </u>		
AZ			\$	\$			<u> </u>		
AR			\$	\$	1		5		
CA		Х	§ 15,000,000.00	5	10,614,000.00	0	0.00		х
со			\$	\$	· · · · · · · · · · · · · · · · · · ·		5		
СТ		Х	§ 15,000,000.00	1 5	2,924,000.00	0	0.00		х
DE	ļ		\$	5	3		5		
DC	ļ		\$	\$)		5		
FL			\$	\$)		\$		
GA			\$		<u> </u>				
HI			\$	\$	S		5	ļ 	
ID			\$	\$	<u> </u>		<u> </u>		
IL	<u> </u>		\$	\$	<u> </u>		5		
IN			\$	\$	S		5		
IA			\$	\$	<u> </u>		5		
KS			\$	5	S		<u> </u>		
KY			\$	8	S				
LA			\$	5	8		5		
ME			\$	5	8				
MD			\$		8		<u> </u>		
MA			\$	5	S		5	<u> </u>	
MI			\$	\$	<u> </u>		5	-	
MN			\$	\$	S		\$		
MS			\$	5	S		<u> </u>		
МО			\$	ļ ş	S		\$		

, ,					APPENDIX				
1	Intend to r accre inves St	to sell non- edited tors in ate	Type of Security and aggregate offering price offered in state (Part C-Item 1)		amount pur	investor and rehased in State C-Item 2)		Disqual under UI (if yes explan waiver	ification State OE , attach ation of granted) -Item 1)
State	Yes	No	Series B Convertible Preferred Stock	Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
MT			\$		8		5		
NE			\$		5		5		
NV			\$		<u> </u>		S		
NH			\$		6		\$		
NJ			\$		8		5		
NM			\$		3		5		
NY			\$		8		5		
NC			**************************************		5		\$		
ND			\$		<u> </u>		5		
ОН			\$		S		\$		
OK			\$		5		\$		
OR			\$		\$				
PA			\$		5		5		
RI			\$		5		S		
SC			\$		5		\$		
SD			\$		<u> </u>		\$		
TN		х	§ 15,000,000.00	2	1,462,000.00	0	\$ 0.00	1	х
ТX			\$		B	:	\$	<u> </u>	
UΤ			\$		ß		\$		
VT			\$		B		5		
VA			\$		<u> </u>		6		
WA	<u> </u>		\$		S		\$		
WV			\$		\$		\$		
WI	 		\$		<u> </u>		\$		
WY PR	<u> </u>		р \$		5		φ 5		
FOR			\$		§		\$		
	Totals	as of		8	5 15,000,000.00	0	\$ 0.00		